Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

We conducted a retrospective case-control study using subjects enrolled between 2002 and 2015 in a population-based biobank. Cases were healthy at enrollment but subsequently developed an incident ...

Cases Studied-Experience of an Ent Department in Senegal INTRODUCTION: Thyroid disease in men is rare and often associated ...

New research, with the caveat of a relatively short follow-up, adds to encouraging data showing an overall low risk of the development of thyroid cancer associated with glucagon-like peptide 1 ...

In the largest study of its kind involving a diabetic population, the use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs shows no significantly increased risk for thyroid cancer, with ...

The study-a collaborative effort involving multiple Yale departments and institutions across the U.S.-found a "significant association" between exposure to ambient fine particulate matter air ...

For all the buzz surrounding Ozempic and similar GLP-1 drugs for weight loss, there are also plenty of concerns about potential serious or long-term side effects. Among the scariest of these fears is ...

Researchers from the Endocrine Tumors group at the Germans Trias i Pujol Research Institute (IGTP), in collaboration with five university hospitals, have conducted the first comprehensive study of DNA ...

Data from the GBD 2021 were used. The estimated annual percentage changes (EAPCs) were used to assess the trends in thyroid cancer. Decomposition analysis was used to identify the factors contributing ...

Thyroid cancer surgery involves removing part or all of the thyroid gland to treat cancerous growths. It is the primary treatment for most thyroid cancers. Thyroid cancer develops when cells in the ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence suggests.